Genetic polymorphisms of paraoxonase 1 and susceptibility to atherogenesis

Srpski Arhiv za Celokupno Lekarstvo

Volumn 141, Issue 9-10, 2013, Pages 629-633

  Grubiša, Ivana ^a   Otašević, Petar ^b,c   Dimković, Nada ^a,b   Nedeljković, Ivana ^b   Toljić, Boško ^b   Vučinić, Nada ^a  

^a ZVEZDARA UNIVERSITY MEDICAL CENTER   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Dedinje Cardiovascular Institute ^*  (Serbia)

Author keywords

Atherogenesis; Gene polymorphisms; Oxidative stress; Paraoxonase 1

Indexed keywords

ARYLDIALKYLPHOSPHATASE;

ADULT; AGED; ATHEROSCLEROSIS; CASE CONTROL STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; MIDDLE AGED; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PROMOTER REGION; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 84911028041     PISSN: 03708179     EISSN: None     Source Type: Journal    
DOI: 10.2298/SARH1310629G     Document Type: Article

References (26)

1. World Health Organization (WHO) [Internet] 2011. Noncommunicable diseases country profiles 2011. Available from: http://www.who.int/nmh/publications/ncd_profiles2011/en/.
2. Futterman LG, Lemberg L. Fifty percent of patients with coronary artery disease do not have any of the conventional risk factors. Am J Crit Care. 1998; 7(3):240-4.
3. Mackness M, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991; 286(1-2):152-4. Erratum in: FEBS Lett 1991; 292(1-2):307.
4. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics. 1996; 33(3):498-507.
5. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/ arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993; 53:598-608.
6. Humbert R, Adler DA, Disteche CM, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase polymorphisms. Nat Genet. 1993; 3(1):73-6.
7. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet. 2001; 68(6):1428-36.
8. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol. 2000; 20(2):516-21.
9. Costa LG, Cole TB, Furlong CE. Paraoxonase (PON1): from toxicology to cardiovascular medicine. Acta Biomed. 2005; 76 Suppl 2:50-7.
10. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res. 2006; 47(11):2492-502.
11. Flekač M, Škrha J, Zídková K, Lacinová Z, Hilgertová J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res. 2008; 57(5):717-26.
12. Aviram M, Kaplan M, Rosenblat M, Fuhrman B. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharmacol. 2005; (170):263-300.
13. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes. Atherosclerosis. 2006; 187(1):74-81.
14. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonase (PON) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000; 101(21):2510-7.
15. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997; 99(8):2005-19. Erratum in J Clin Invest. 1997; 99(12):3043.
16. Bayrak A, Bayrak T, Tokgözoǧlu SL, Volkan-Salanci B, Deniz A, Yavuz B, et al. Serum PON1-1activity but not Q192R polymorphism is related to the extent of atherosclerosis. J Atheroscler Thromb. 2001; 18:1-9.
17. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Fins. J Clin Invest. 1996; 98(4):883-5.
18. Leviev I, Deakin S, James RW. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res. 2001; 42(4):528-35.
19. Djurić G, Svetel M, Nikolaević SI, Dragadević N, Gavrilović J, Kostić VS. Polymorphisms in the genes of cytochrome oxidase P450 2D6 (CYP2D6), paraoxonase 1 (PON1) and apolipoprotein E (APOE) as risk factors for Parkinson's disease. Vojnosanit Pregl. 2007; 64(1):25-30.
20. Taşkiran P, Cam SF, Sekuri C, Tüzün N, Alioǧlu E, Altintaş N, et al. The relationship between paraoxonase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Turk Kardiyol Dern Ars. 2009; 37(7):473-8.
21. Parra S, Alonso-Villaverde C, Coll B, Ferré N, Marsillach J, Aragonès G, et al. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Atherosclerosis. 2007; 194(1):175-81.
22. Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, TrimarchiG, et al. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr Med Res Opin. 2005; 21(5):777-84.
23. Clarimon J, Eerola J, Hellström O, Tienari PJ, Singleton A. Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population. Neurosci Lett. 2004; 367(2):168-70.
24. Grdić M, Barišić K, Rumora L, Salamunić I, Tadijanović M, Žanić-Grubišić T, et al. Genetic frequencies of paraoxonase 1 gene polymorphisms in Croatian population. Croat Chem Acta. 2008; 81:105-11.
25. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Garin MC. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk 173 factor for coronary heart disease in type 2 diabetic patients. Diabetes. 2000; 49(8):1390-3.
26. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms i 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 2004; 363(9410):689-95.